Release Date: April 29, 2022
Expiration Date: January 5, 2024
Activity Overview
This Oncology Consultations™ online activity includes leading myeloproliferative neoplasm (MPN) experts discussing patient management and treatment issues across the PV continuum of care. The latest clinical updates related to disease management and an in-depth look at challenging cases in this space are considered. Expert thought leaders reveal their unique approach to treatment, based on clinical specialty and individual practice setting in this engaging, multimedia consultation format that includes videos integrated with slides and case-based elements.
Target Audience
This educational activity is directed toward medical oncologists and hematologists who are involved in the treatment of MPNs.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to
- Discuss the role of clinical and cytogenic characteristics on risk stratification and treatment planning in the management of polycythemia vera (PV)
- Describe the mechanistic rationale of PV therapeutic approaches in the context of the current treatment landscape
- Apply recent trial findings on emerging treatment regimens to optimize clinical decision-making and care for patients with PV
John Mascarenhas, MD
Director, Adult Leukemia Program
Leader, Myeloproliferative Neoplasm Clinical Research
Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York
Disclosures: Grant/Research Support: Incyte, CTI BioPharma, Geron, AbbVie, Kartos Therapeutics, PharmaEssentia, Bristol Myers Squibb, Celgene, Roche, and Novartis; Consultant: Incyte, CTI BioPharma, Geron, Abbvie, Kartos Therapeutics, PharmaEssentia, Bristol Myers Squibb, Celgene, Roche, Novartis, Constellation Pharmaceuticals, Sierra Oncology, Karyopharm Therapeutics, Galecto Biotech.
Nikolai A. Podoltsev, MD, PhD
Associate Professor, Hematology
Yale School of Medicine
New Haven, Connecticut
Disclosures: Grant/Research Support (paid to institution): Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI BioPharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals, Kartos Therapeutics; Consultant: Blueprint Medicines, Incyte, Novartis, Celgene, Bristol Myers Squibb, CTI BioPharma, PharmaEssentia, Constellation Pharmaceuticals, Cogent Biosciences, AbbVie.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here